Free Trial
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price, News & Analysis

Seres Therapeutics logo
$11.36 +0.50 (+4.56%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$11.94 +0.58 (+5.11%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Seres Therapeutics Stock (NASDAQ:MCRB)

Key Stats

Today's Range
$10.69
$12.18
50-Day Range
$6.77
$11.36
52-Week Range
$6.53
$30.60
Volume
107,170 shs
Average Volume
134,800 shs
Market Capitalization
$99.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.67
Consensus Rating
Reduce

Company Overview

Seres Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

MCRB MarketRank™: 

Seres Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 1204th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Seres Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.

  • Amount of Analyst Coverage

    Seres Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Seres Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Seres Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Seres Therapeutics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Seres Therapeutics has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Seres Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.55% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently decreased by 4.47%, indicating that investor sentiment is improving.
  • Dividend Yield

    Seres Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Seres Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.55% of the float of Seres Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Seres Therapeutics has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Seres Therapeutics has recently decreased by 4.47%, indicating that investor sentiment is improving.
  • Search Interest

    5 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Seres Therapeutics is held by insiders.

  • Percentage Held by Institutions

    59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Seres Therapeutics' insider trading history.
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

MCRB Stock Analysis - Frequently Asked Questions

Seres Therapeutics' stock was trading at $16.62 at the start of the year. Since then, MCRB shares have decreased by 31.7% and is now trading at $11.3550.

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Wednesday, May, 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.67) by $1.57.
Read the conference call transcript
.

Seres Therapeutics shares reverse split on the morning of Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), QUALCOMM (QCOM) and NIO (NIO).

Company Calendar

Last Earnings
5/07/2025
Today
7/03/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$73.67
High Stock Price Target
$200.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+548.8%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$140 thousand
Pretax Margin
N/A
Return on Equity
-41,084.76%

Debt

Sales & Book Value

Annual Sales
$126.32 million
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
7.05

Miscellaneous

Free Float
8,322,000
Market Cap
$99.13 million
Optionable
Optionable
Beta
2.75

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MCRB) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners